Source comparison
IGF-1 LR3 vs CJC-1295 for Muscle Research UK 2026
All compounds discussed in this article are intended exclusively for laboratory and preclinical research purposes. None of the peptides referenced here are approved for human administration, therapeutic use, or clinical application. This content is directed at
This comparison does not assign a generated winner or score.
- All compounds discussed in this article are intended exclusively for laboratory and preclinical research purposes. None of the peptides referenced here are approved for human administration, therapeutic use, or clinical application. This content is directed at qualified researchers operating within appropriate regulatory and ethical frameworks.
- IGF-1 LR3 and CJC-1295 both ultimately converge on skeletal muscle anabolism, yet their pharmacological mechanisms are fundamentally different: IGF-1 LR3 acts as a direct, long-acting IGF-1 receptor agonist that bypasses the hypothalamic-pituitary axis entirely, while CJC-1295 is a GHRH analogue that stimulates endogenous GH pulses from the pituitary, which then drives hepatic IGF-1 synthesis over hours. This comparison is mechanistically distinct from IGF-1 LR3 vs MGF (ID 77399, which covers local satellite cell biology versus systemic signalling), the CJC-1295 muscle post (ID 77296, which covers GH axis and protein synthesis in depth), and the GH secretagogue hub (ID 77059) — this comparison focuses specifically on the mechanistic differences in how each compound reaches and activates skeletal muscle IGF-1R, the downstream signalling divergences, and what this means for muscle research protocol design.